Table 2a –

Baseline clinical characteristics

	IDC (all BB)	NF (Control)	F vs. NF	R	NR	R vs. NR
Clinical characteristic	47	4	p	31 (66.0%)	16 (34.0%)	p
Age, years	45.8±13.1	41.0±17.1	0.62	43.8±13.2	49.7±12.3	0.20
HF duration, months	23.5±45.5	-	-	6.8±9.8	55.8±67.0	0.001
Female	13 (27.6%)	1 (25.0%)	1	9 (29.0%)	4 (25.0%)	1
Race			1			0.58
White	31 (66.0%)	4 (100.0%)		22 (71.0%)	9 (56.2%)
Black	6 (12/8%)	0 (0.0%)		4 (12.9%)	2 (12.5%)
Hispanic	7 (14.9%)	0 (0.0%)		4 (12.9%)	3 (18.8%)
Other	3 (6.4%)	0 (0.0%)		1 (3.2%)	2 (12.5%)
NYHA class			0.002			0.55
I	0 (0.0%)	2 (50.0%)		0 (0.0%)	0 (0.0%)
II	26 (55.3%)	2 (50.0%)		16 (51.6%)	10 (62.5%)
III	21 (44.7%)	0 (0.0%)		15 (48.4%)	6 (37.5%)
Atrial fibrillation	10 (21.3%)	1 (25.0%)	1	4 (12.9%)	6 (37.5%)	0.07
Hypertension	18 (38.3%)	2 (50.0%)	0.64	15 (48.4%)	3 (18.8%)	0.06
Creatinine clearance, ml/min	80.1±21.5	87.8±7.9	0.59	85.4±18.4	71.0±26.2	0.04

IDC=Idiopathic dilated cardiomyopathy; BB=β-blocker; F=Failing; NF=Non-failing; R=Responder; NR=Nonresponder